Breaking News
Black Friday SALE: Up to 54% off InvestingPro! Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Bluebird bio Inc (BLUE)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Bluebird's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
10.50 -0.26    -2.42%
26/11 - Closed. Currency in USD ( Disclaimer )
After Hours
10.40
-0.10
-0.95%
16:28:28 - Real-time Data
Type:  Equity
Market:  United States
ISIN:  US09609G1004 
CUSIP:  09609G100
  • Volume: 1,909,264
  • Bid/Ask: 10.40 / 11.00
  • Day's Range: 10.35 - 10.89
Bluebird 10.50 -0.26 -2.42%
Latest Release

Nov 05, 2021

EPS / Forecast

-3.16 / -1.59

Revenue / Forecast

22.68M / 37.21M

Revenue
EPS
 Forecast
 
Release Date Period End EPS /  Forecast Revenue /  Forecast
Feb 23, 2022 12/2021 -- /  -1.83 -- /  4.23M
Nov 05, 2021 09/2021 -3.16 /  -1.59 22.68M /  37.21M
Aug 09, 2021 06/2021 -3.58 /  -3.27 7.47M /  16.28M
May 05, 2021 03/2021 -3.07 /  -3.02 12.79M /  11.55M
Feb 23, 2021 12/2020 -3.01 /  -2.97 10.71M /  14.65M
Nov 04, 2020 09/2020 -2.94 /  -3.05 19.27M /  24.32M
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BLUE Comments

Write your thoughts about Bluebird bio Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ra Pa
Ra Pa Nov 08, 2021 10:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
falling like a little stone down a chasm
Bm Bendary
Bm Bendary Nov 05, 2021 9:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The stock appears here at Investing.com gaining .2% at 16.4 usd?
Bm Bendary
Bm Bendary Nov 05, 2021 9:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
As if yesterday closing was 16:30!
Ra Pa
Ra Pa Nov 05, 2021 7:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why so much down again?
John Brand
John Brand Nov 05, 2021 7:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
TSVT tax-free dividend distribution
Ra Pa
Ra Pa Nov 05, 2021 7:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ok thanks, any value left on this or should we sell the old stock?
Eduardo Camillo
Eduardo Camillo Oct 23, 2021 3:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dear bluebird bio, Inc. Stockholder:In January 2021, we announced a transformative milestone for bluebird bio, Inc.—our intent to separate our oncology portfolio and programs from our severe genetic disease portfolio and programs, thereby creating two independent, publicly traded companies. The strategic objectives of the separation are to unlock value, enhance operational performance and strategic flexibility and tailor the capital structures to best serve these distinct businesses.We believe the best way to realize the full potential of this separation is for bluebird bio, Inc. and 2seventy bio, Inc. to operate independently, with distinct management teams and boards of directors dedicated to their unique business strategies. Through this separation, we have the potential to create two focused, durable businesses that are well-positioned with the resources, talent and foundation to be industry leaders in their respective fields.Going forward, bluebird bio, Inc. intends to focus primarily on its programs in severe genetic disease, including betibeglogene autotemcel (beti-cel; formerly LentiGlobin gene therapy for β-thalassemia), LentiGlobin gene therapy for sickle cell disease, and elivaldogene autotemcel (eli-cel; formerly Lenti-D gene therapy for cerebral adrenoleukodystrophy). 2seventy bio, Inc. plans to focus primarily on the discovery and development of novel engineered cell therapies for cancer, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. 2seventy bio, Inc. expects to commercialize idecabtagene vicleucel (ide-cel; being commercialized as Abecma) in the United States and develop bb21217 through its collaboration arrangement with Bristol-Myers Squibb.Upon completion of the separation, 2seventy bio, Inc. will be spun out of bluebird bio, Inc. and established as an independent, publicly traded company. The separation is anticipated to be generally tax-free to bluebird bio, Inc. stockholders. Under the terms of the distribution, each bluebird bio, Inc. stockholder will receive one share of 2seventy bio, Inc. common stock for every three shares of bluebird bio, Inc. common stock held of record on October 19, 2021, the record date for the distribution. You do not need to take any action to receive the common stock of 2seventy bio, Inc. to which you are entitled as a bluebird bio, Inc. stockholder as of the record date.Please read the attached information statement, which is being shared with all bluebird bio, Inc. stockholders as of the record date for the distribution. It describes the separation in detail and contains important information about bluebird bio, Inc. and 2seventy bio, Inc.We thank you for your continued support of bluebird bio, Inc. Sincerely,Daniel S. LynchChairman of the Boardbluebird bio, Inc.
Eduardo Camillo
Eduardo Camillo Oct 23, 2021 3:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dear Future 2seventy bio, Inc. Stockholder:On behalf of the entire future 2seventy bio, Inc. team, I am pleased to welcome you as a future stockholder of our new company.2seventy bio, Inc. will be a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. Its programs will be based on chimeric antigen receptor (CAR) technology and T cell receptor technology. At launch, 2seventy bio, Inc.’s programs will include idecabtagene vicleucel; ide-cel, or Abecma, and bb21217, CAR-T cell product candidates for the treatment of multiple myeloma, which are partnered under a collaboration arrangement with Bristol-Myers Squibb. We believe our team’s expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies will enable us to develop a pipeline of highly innovative, targeted cellular therapies for patients with cancer.Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “TSVT” in connection with the distribution of our company’s common stock by bluebird bio, Inc.I invite you to learn more about 2seventy bio, Inc. by reviewing the enclosed information statement. We look forward to our future as an independent company, and to your support as a 2seventy bio, Inc. stockholder as we begin this new and exciting chapter.Sincerely,Nick LeschlyChief Executive Officer2seventy bio, Inc.
Thierry Maa
Thierry Maa Aug 16, 2021 10:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Falling knife
игорь рудов
игорь рудов Aug 10, 2021 12:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I believe that shareholders and the board of directors should force Nick Leschly to leave. he is not able to manage the company well and make it profitable. this will be well received by investors. this is now one of his few steps that will make the price rise.
Ab High
Ab High Aug 09, 2021 3:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
18soon
Ivan John
Ivan_John May 24, 2021 3:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
To the moon.
Bobo Müller
Bobo Müller May 24, 2021 3:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Go back to GME
Robin Clerici
Robin Clerici May 21, 2021 2:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
good move today
James Wentz
James Wentz Apr 20, 2021 2:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
great news,blue will be moving up soon since they moved away from Germany 🇩🇪
mick ninja
mick ninja Apr 09, 2021 1:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why red ? 34 at 28 ... disgusting
mick ninja
mick ninja Apr 08, 2021 10:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why red? forever red?
mick ninja
mick ninja Apr 01, 2021 1:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://endpts.com/bristol-myers-squibb-faces-1b-tax-lawsuit-after-accidental-disclosure-reveals-alleged-offshore-patents-scheme-report/
Thierry Maa
Thierry Maa Mar 30, 2021 9:38AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why does it go down?
Alex Sergeev
Alex Sergeev Mar 30, 2021 9:38AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
honest answer - nobody knows
Boris Borisov
Boris Borisov Mar 29, 2021 12:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Obviously there is a serious problem if it doesn't fly into space with such news ... Skeletons in the wardrobe or too much debt ???
Calin Calin
Calin Calin Mar 29, 2021 12:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Or just big market manipulation.
Thierry Maa
Thierry Maa Mar 29, 2021 11:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
should be much higher - any bad news its -40% and good news +4%???!!!
mick ninja
mick ninja Mar 29, 2021 11:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
if it were so easy to find a correlation on the stock exchange and on pharma stocks ...
Thierry Maa
Thierry Maa Mar 29, 2021 7:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pre-market not picking up !!
Serdar Ates
Serdar Ates Mar 28, 2021 2:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
FDA approval with short sqeuze Blue will hit 50+ on Monday.
Erik Kraft
Erik Kraft Mar 28, 2021 2:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I hope we will close that gap
mick ninja
mick ninja Mar 28, 2021 2:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Now down 29$ not 50
Serdar Ates
Serdar Ates Mar 28, 2021 2:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma
Serdar Ates
Serdar Ates Mar 28, 2021 2:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Monday gaps up 40%
mick ninja
mick ninja Mar 28, 2021 2:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Serdar Ates gap down monster -10%
Erik Kraft
Erik Kraft Mar 27, 2021 9:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
FDA approved!
Ivan John
Ivan_John Mar 25, 2021 7:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
FDA approves this stock
Calin Calin
Calin Calin Mar 25, 2021 7:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Up we go!
Arl Nn
ArlN Mar 15, 2021 6:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
27th March, this should recover nicely
Tiffa Lovina
Tiffa Lovina Mar 15, 2021 6:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what happen on 27th march?
Arl Nn
ArlN Mar 15, 2021 6:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
There is a FDA priority approval coming for one of their trial
Thierry Maa
Thierry Maa Mar 15, 2021 6:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Approved :) monday +30%
mick ninja
mick ninja Mar 15, 2021 6:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
....
Eduardo Camillo
Eduardo Camillo Mar 04, 2021 10:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Caiu mais. FDA não aprovou.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email